messaggio

clik on the image and visit the new site

New site clik on the image

"In silico"


From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Wednesday 20 January 2016

href="https://www.phagetherapycenter.com/pii/PatientServlet?command=static_faq&secnavpos=7&language=0#staphusa">How prevalent are Staphylococcus aureus infections, and what is the average cost of conventional antibiotic treatment in the United States?
What is an autoPhage?
What infections / conditions are not treatable with phage therapy?

Friday 20 June 2014

Web site change of address

After 2 years I check the "State of'Art" about Phage Therapy another time.

This is the new address : link.

Wednesday 5 March 2014

ATTENTION !!!!


Confusion by too much technology : Google and  android mobile.
The final result is that all  my images  are disappeared.


Wednesday 2 October 2013

After one year what's happened now about phage therapy ? Something must have happened.

1.
the project was launched on June 1st 2013 and will last 27 months

Comment: I am happy about this work but not for mycobacteriophage choice.The same phages are used in all works with mycobacteria (the host range for D29 is very large and includes both slow and fast-growing species). This aspect ( this is my opinion) is not a favourable point for phage therapy in Buruli: we must wait until a specific phage for Mycobacterium ulcerans strain is isolated together in the same country.
This work supports the timeliness of phage therapy before the infection to become chronic (33 days) and confirms my working hypothesis: a,b,c

Friday 18 May 2012

Wednesday 15 February 2012

Indian TB cases 'can't be cured' ( but DS6A phage could be used)


 DS6A phage (my old idea)

From this scientific work :
" In 1981 Sula et al. reported positive indicators
with a reduction in the observed lesions in the spleen, lungs and livers of guinea pigs following therapy with DS-6A. More recent work demonstrated that phage therapy could have a beneficial effect in guinea pigs with disseminated tuberculosis, but that its action
was considerably less pronounced than that of isoniazid monotherapy."


From this scientific work
"Sula et al. [63] infected guinea pigs with M. tuberculosis and then treated them with subcutaneous injections of three different bacteriophages twice weekly for 10 weeks.
One of these bacteriophages, designated DS-6A, produced an antibacterial effect at least as good as isoniazid."



From this scientific work:
"In addition, the previously isolated phage DS6A, the only one of the 138 phages that does not infect M. smegmatis was sequenced and annotated." 


From this scientific work:




Sunday 22 January 2012

ISTC Databases

From this web site




If you write " Bacteriophage Therapy" in the small window you found a lot of scientific projects about Phage therapy.

Nina Chanishvili:Innovative Drug Discovery Workshop, ISTC, Toronto, Canada, 6-10 August, 2011


From this document